Clinical Relevance of uPA, uPAR, PAI 1, PAI 2, Tissue Expression and Plasma PAI 1 Level in Colorectal Carcinoma Patiens
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F11%3A%230001449" target="_blank" >RIV/65269705:_____/11:#0001449 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.5754/hge10232" target="_blank" >http://dx.doi.org/10.5754/hge10232</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5754/hge10232" target="_blank" >10.5754/hge10232</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Clinical Relevance of uPA, uPAR, PAI 1, PAI 2, Tissue Expression and Plasma PAI 1 Level in Colorectal Carcinoma Patiens
Popis výsledku v původním jazyce
BACKGROUND/AIMS: Urokinase (uPA) is a serine protease, which together with uPAR, tPA, PAI 1 and PAI 2 forms the plasminogen activator system, a component of metastatic cascade contributing to the invasive growth and angiogenesis of malignant tumours. METHODOLOGY: Both preceding therapy and after 6-8 weeks of the treatment, plasma PAI 1 levels (photometric microplate method on the ELISA) and uPA, uPAR, PAI 1 and PAI 2 tissue expression (immunohistochemical reaction) were analysed from 80 colorectal carcinoma patients. RESULTS: Analysis showed higher pre-treatment plasma levels of PAI 1 in patients with advanced tumours, which decreased after surgery or the start of therapy (p=0.004); Patients with higher plasma level PAI 1 before (0.013) and after therapy (0.004) had significantly shorter survival. There was a higher expression of uPA (p<0.001), uPAR (p<0.001), PAI 1 (p=0.042) and PAI 2 (p<0.001) in advanced colorectal carcinoma. A relationship between PAI 2 (p=0.010) and uPAR (p=0.019)
Název v anglickém jazyce
Clinical Relevance of uPA, uPAR, PAI 1, PAI 2, Tissue Expression and Plasma PAI 1 Level in Colorectal Carcinoma Patiens
Popis výsledku anglicky
BACKGROUND/AIMS: Urokinase (uPA) is a serine protease, which together with uPAR, tPA, PAI 1 and PAI 2 forms the plasminogen activator system, a component of metastatic cascade contributing to the invasive growth and angiogenesis of malignant tumours. METHODOLOGY: Both preceding therapy and after 6-8 weeks of the treatment, plasma PAI 1 levels (photometric microplate method on the ELISA) and uPA, uPAR, PAI 1 and PAI 2 tissue expression (immunohistochemical reaction) were analysed from 80 colorectal carcinoma patients. RESULTS: Analysis showed higher pre-treatment plasma levels of PAI 1 in patients with advanced tumours, which decreased after surgery or the start of therapy (p=0.004); Patients with higher plasma level PAI 1 before (0.013) and after therapy (0.004) had significantly shorter survival. There was a higher expression of uPA (p<0.001), uPAR (p<0.001), PAI 1 (p=0.042) and PAI 2 (p<0.001) in advanced colorectal carcinoma. A relationship between PAI 2 (p=0.010) and uPAR (p=0.019)
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Ostatní
Rok uplatnění
2011
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Hepato-Gastroenterology
ISSN
0172-6390
e-ISSN
—
Svazek periodika
58
Číslo periodika v rámci svazku
112
Stát vydavatele periodika
GR - Řecká republika
Počet stran výsledku
8
Strana od-do
1918-1925
Kód UT WoS článku
000300532700015
EID výsledku v databázi Scopus
—